<乌鸦传媒>More Intense ALL Therapy Improves Outcomes in Adolescents, Young Adults Treatment with "pediatric-inspired protocols" improved event-free, relapse-free survival Sep 07, 2023
<乌鸦传媒>Non-Covalent BTK Inhibitor Yields High Response Rate in Pretreated CLL 73% of patients with prior exposure to covalent BTK inhibitors responded Jul 05, 2023
<乌鸦传媒>WHO Links Sweetener to Cancer; Younger-Age CRC Risk; PCOS and Ovarian Cancer News, features, and commentary about cancer-related issues Jun 29, 2023
<乌鸦传媒>No OS Benefit With Ibrutinib in Early-Stage, High-Risk CLL Study suggests "watch and wait" should remain standard of care Jun 28, 2023
<乌鸦传媒>Earlier Detection of Cardiac Dysfunction Possible for Young Adult Cancer Survivors A case for monitoring global longitudinal strain despite normal LVEF Jun 20, 2023
<乌鸦传媒>Pushback on Price Negotiation; Genetic Testing Lags; More Foreign Help for Shortages News, features, and commentary about cancer-related issues Jun 15, 2023
<乌鸦传媒>Base-Edited CAR-T Product 'Potent' in Relapsed Childhood T-Cell ALL One young patient achieved molecular remission within 28 days of infusion Jun 14, 2023
<乌鸦传媒>CAR-T for Chronic Lymphocytic Leukemia Hits Goal of Mid-Stage Trial All patients had progressed on BTK inhibitors and most had failed venetoclax Jun 12, 2023
<乌鸦传媒>Cross-Border Collaboration Improves Survival in Pediatric Leukemia Patients 5-year OS increased to 100% in standard-risk ALL patients at a Tijuana hospital May 25, 2023
<乌鸦传媒>Adding Mylotarg to Chemo Fails to Boost Survival in NPM1-Mutated AML But trial detects "meaningful benefit" when it comes to relapse, editorialists say May 15, 2023
<乌鸦传媒>FLT3 Inhibitor Doubles Overall Survival in Acute Myeloid Leukemia Median OS improved from 15 months to nearly 32 months with quizartinib May 09, 2023
<乌鸦传媒>Blinatumomab Plus Chemo Effective in Aggressive Infant ALL Low incidence of relapse after treatment "remarkable," researchers say Apr 26, 2023
<乌鸦传媒>Targeted Agents Go Head-to-Head for Newly Diagnosed Ph+ ALL Trial crowns a winner, but how relevant is it amid the changing therapeutic landscape for ALL? Feb 16, 2023
<乌鸦传媒>The 'Extreme' Story of How Two Game-Changing Cancer Drugs Came to Market New book by former Forbes senior editor pulls back the curtain on drug development Feb 13, 2023
<乌鸦传媒>Off-the-Shelf T-Cell Therapy Effective Against Viral Infections After Allo-HCT Produced an antiviral response in 95% of patients with six different types of infection Jan 13, 2023
<乌鸦传媒>Zanubrutinib Shows Good Tolerance in BTK-Inhibitor Intolerant Malignancies Most patients had no recurrence of their original intolerance event Jan 10, 2023
<乌鸦传媒>Crystal Ball Cloudy for PI3K Inhibitors' Future in Hematology After a year of negative news, some caution about throwing out the baby with the bath water Jan 02, 2023
<乌鸦传媒>New Regimen for GvHD Prophylaxis in Well-Matched Reduced-Intensity Allo-HCT Post-transplant cyclophosphamide, tacrolimus, and MMF reduces GvHD without higher relapse risk Dec 14, 2022
<乌鸦传媒>'Practice-Changing' Results With Zanubrutinib Versus Ibrutinib in CLL/SLL Significantly longer PFS with second-gen BTK inhibitor in relapsed/refractory disease Dec 14, 2022
<乌鸦传媒>Blinatumomab-Chemo Consolidation a 'New Standard' in MRD-Negative B-ALL Phase III study showed 58% reduction in the risk of death versus chemo alone Dec 13, 2022
<乌鸦传媒>AML Study Suggests Intensive Chemo Unnecessary Before Allo-HCT Similar outcomes if patients went directly to transplant or received intensive salvage first Dec 11, 2022
<乌鸦传媒>Rigid In-Hospital Diet Offers No Advantage in Patients After HSCT "We should eliminate these silly neutropenic diets," expert says Dec 10, 2022
<乌鸦传媒>Year in Review: Acute Lymphoblastic Leukemia New ways to use CAR T-cell therapy and treatment de-intensification strategies Dec 05, 2022
<乌鸦传媒>New IDH1 Inhibitor Wins FDA Approval for Acute Myeloid Leukemia Olutasidenib led to a 35% response rate in a study of adults with previously treated AML Dec 02, 2022
<乌鸦传媒>Transplant With Orca-T Reduced GVHD in Hematologic Malignancies Risk of relapse was also lower in the group who received the cell therapy Oct 03, 2022
<乌鸦传媒>Response-Based Ponatinib Dose Reduction a Win-Win in Chronic-Phase CML? Strategy applied in OPTIC trial may mitigate adverse events without sacrificing benefit Sep 29, 2022
<乌鸦传媒>Magrolimab-Azacitidine Shows Promise in Untreated High-Risk MDS About a third of patients, including those with TP53 mutations, achieved complete remission Sep 29, 2022
<乌鸦传媒>'Unparalleled Times' in Hematology, but Workforce Issues Persist "This is the most exciting time ever" to be a hematologist, says ASH President Jane Winter, MD Sep 26, 2022 video
<乌鸦传媒>What's on Tap at the Society of Hematologic Oncology's 10th Annual Meeting Emphasis on novel biological approaches in treating patients with hematologic malignancies Sep 26, 2022
<乌鸦传媒>CAR-T Therapy Effective in Youngest Kids With ALL Analysis shows safety and outcomes equivalent to those reported in older children Sep 08, 2022
<乌鸦传媒>Low-Dose Hypomethylating Agents in Lower-Risk MDS Yield Promising Outcomes Overall response rates were 67% with decitabine, 48% with azacitidine Aug 22, 2022
<乌鸦传媒>Two More Patients With HIV Surviving Without Antiretrovirals Functional cures now seen in 5 patients Jul 29, 2022
<乌鸦传媒>'Rogue' Online Pharmacies Are Dispensing Cancer Drugs Shady sites with little oversight are selling imatinib for much less than U.S. retail price Jul 29, 2022
<乌鸦传媒>Zanubrutinib Wins in First-Line CLL for Older Patients The BTK inhibitor proves superior to bendamustine-rituximab in phase III trial Jul 08, 2022
<乌鸦传媒>FDA Warns of Increased Mortality Risk With Duvelisib Drug approved for adults with CLL/SLL Jul 01, 2022
<乌鸦传媒>FDA Panel Backs Gene Tx for Degenerative Brain Disorder in Kids Advisers unanimously recommend approval for pediatric ALD patients without HLA-matched donors Jun 10, 2022
<乌鸦传媒>FDA Pulls Lymphoma Approvals for PI3K Inhibitor Umbralisib Worse overall survival observed despite improvements in progression-free survival Jun 01, 2022
<乌鸦传媒>Allo-Transplant With Omidubicel Hints at Longer-Term Benefits Too "Viable" option for patients eligible for umbilical cord blood transplantation, investigator says Apr 27, 2022
<乌鸦传媒>Eprenetapopt-Based Combo Impresses in TP53-Mutant AML/MDS 1-year relapse-free survival rate of 60% with maintenance therapy after transplant Apr 25, 2022
<乌鸦传媒>9/11 Responders More Likely to Carry Genetic Mutations Tied to Cancer Clonal hematopoiesis seen in 10% of firefighters, medical personnel on the scene after WTC attack Mar 07, 2022
